arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Spyre Therapeutics, Inc.

SYRE
$96.58 ▼ -2.62 (-2.64%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
49 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
39
Health
Weak
Neutral
auto_awesome

Analytical Summary

Spyre Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap —
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -10.1% ↘
FCF / Share None
Trailing P/E —
Price / Book 8.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

49-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-69.00M
↓ -54.1% —
Operating Margin Operating profit as % of sales
-49.0%
↑ +88.0% —
FCF / Share Free cash flow per share
$-0.78
↓ -317.9% —

Health Breakdown

Returns ↑
27
Cash Quality ↑
69

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 13 years · 49 quarters